中国医学创新Issue(28)：37-38,2.DOI:10.3969/j.issn.1674-4985.2012.28.021
肿瘤坏死因子拮抗剂(TNF-α)治疗强直性脊柱炎临床不良反应观察
Tumor Necrosis Factor (TNF-alpha) Treatment of Ankylosing Spondylitis Clinical Adverse Reactions Observed
徐刚1
作者信息
- 1. 江苏省徐州大屯煤电公司中心医院 江苏 徐州 221611
- 折叠
摘要
Abstract
Objective:To learn about the common and the rare adverse reactions taking place in the clinical treatment of ankylosing spondylitis with tumor necrosis factor (TNF) antagonist.Method:50 cases of patients were enrolled in this group receiving TNF antagonist (the product used in this group was Etanercept from Shanghai CP Guojian Pharmaceutical Co,Ltd) for treating ankylosing spondylitis.In addition,the incidence of adverse reactions and the common reverse reactions were observed.Result:Of the 50 patients received TNF antagonist for treating ankylosing spondylitis,first-dosage adverse reactions occurred in eight cases and medium or long-term adverse reactions occurred in 5 cases.Conclusion:The usage of biological agent in the treatment of ankylosing spondylitis is considered as a safe and efficacious approach,in which the occurrence and management of the adverse reactions should be concerned.关键词
脊柱炎/强直性/肿瘤坏死因子拮抗剂-α/安全性/不良反应Key words
Spondylitis/Ankylosing/Tumour necrosis factor-αblocker/Safety/Untoward effect引用本文复制引用
徐刚..肿瘤坏死因子拮抗剂(TNF-α)治疗强直性脊柱炎临床不良反应观察[J].中国医学创新,2012,(28):37-38,2.
